Table 2.
Clinical trials with RNA-based vaccines against infectious diseases. Data collected from the studies registered at ClinicalTrials.gov as of 8 August 2021.
| Sponsor | NCT-Number | Country | Vaccine Type | Targets | Trial Phase | Status | Reference |
|---|---|---|---|---|---|---|---|
| Argos Therapeutics | NCT00672191 | United States and Canada | DCs loaded with autologous viral antigen and CD40L mRNAs | HIV | 2 | Completed | [128] |
| Massachusetts General Hospital | NCT00833781 | United States | Autologous DCs loaded with viral antigen mRNA | HIV | 2 | Completed | [129] |
| CureVac AG | NCT02241135 | Germany | RNActive viral Ag mRNA | Rabies | 1 | Completed | [130] |
| Moderna Therapeutics | NCT03392389 | United States | Lipid-nanoparticle-encapsulated, chemically modified viral antigen mRNA | Human Metapneumovirus and Human Parainfluenza | 1 | Completed | [131] |
| NCT03014089 | Zika | NA | |||||
| NCT03325075 | Chikungunya | [132] | |||||
| NCT03382405 | Cytomegalovirus | NA | |||||
| NCT03076385 | Germany | Influenza | [133] | ||||
| Fundacion Clinic per a la Recerca Biomédica | NCT02413645 | Spain | Naked Viral antigen and TriMix (CD40, CD70 and IL2) mRNA | HIV | 1 | Completed | [134] |
| AlphaVax | NCT00440362 | United States | Alphavirus replicon vaccine expressing a viral hemagglutinin protein | Influenza | 1/2 | Completed | NA |
| NCT00439803 | Alphavirus replicon vaccine expressing viral genes | Cytomegalovirus | 1 | [135] | |||
| NCT00097838 | United States, Botswana, and South Africa | Alphavirus replicon vaccine expressing viral protein | HIV | [136] |
DCs, dendritic cells; HIV, human immunodeficiency virus; NA, not available.